OpenURL Connection Search

Select item for more details and to access through your institution.

Traitement de maintenance des lymphomes malins non hodgkiniens.
Published in:
Oncologie (Tech Science Press), 2011, v. 13, n. 9, p. 543, doi. 10.1007/s10269-011-2062-4
By:
- Pascal, L.;
- Terriou, L.;
- Morschhauser, F.
Publication type:
Article
Longitudinal study of AMH variations in 122 Adolescents and Young Adults (AYA) and non-AYA lymphoma patients to evaluate the chemo-induced ovarian toxicity to further personalise fertility preservation counselling.
Published in:
2021
By:
- Decanter, C;
- Delepine, J;
- Behal, H;
- Manier, S;
- Bruno, B;
- Barbatti, M;
- Robin, C;
- Labreuche, J;
- Morschhauser, F;
- Pigny, P
Publication type:
journal article
Heterogeneity of protein kinase C β<sub>2</sub> expression in lymphoid malignancies.
Published in:
Histopathology, 2007, v. 50, n. 5, p. 561, doi. 10.1111/j.1365-2559.2007.02666.x
By:
- Decouvelaere, A.-V.;
- Morschhauser, F.;
- Buob, D.;
- Copin, M. C.;
- Dumontet, C.
Publication type:
Article
Non-Hodgkin's lymphoma.
Published in:
Bone Marrow Transplantation, 2002, v. 30, n. 4, p. 229, doi. 10.1038/sj.bmt.1703625
By:
- Yakoub-Agha, I.;
- Fawaz, A.;
- Folliot, O.;
- Guillerm, G.;
- Quesnel, B.;
- Fenaux, P.;
- Bauters, F.;
- Jouet, J.P.;
- Morschhauser, F.
Publication type:
Article
Verträge aus dem Baukasten – Jetzt auch legal — Der BGH beendet das Tauziehen um die Rechtmäßigkeit von sog. Vertragsgeneratoren.
Published in:
Computer und Recht, 2021, v. 37, n. 12, p. 808, doi. 10.9785/cr-2021-371212
By:
- Morschhäuser, Nikolaus F.
Publication type:
Article
Anti-CD22 and anti-CD79B antibody drug conjugates are active in different molecular diffuse large B-cell lymphoma subtypes.
Published in:
2015
By:
- Pfeifer, M;
- Zheng, B;
- Erdmann, T;
- Koeppen, H;
- McCord, R;
- Grau, M;
- Staiger, A;
- Chai, A;
- Sandmann, T;
- Madle, H;
- Dörken, B;
- Chu, Y-W;
- Chen, A I;
- Lebovic, D;
- Salles, G A;
- Czuczman, M S;
- Palanca-Wessels, M C;
- Press, O W;
- Advani, R;
- Morschhauser, F
Publication type:
journal article
Baseline differential blood count and prognosis in CD20-positive post-transplant lymphoproliferative disorder in the prospective PTLD-1 trial.
Published in:
Leukemia (08876924), 2013, v. 27, n. 10, p. 2102, doi. 10.1038/leu.2013.110
By:
- Zimmermann, H;
- Choquet, S;
- Moore, J;
- Salles, G;
- Morschhauser, F;
- Lamy, T;
- Jaccard, A;
- Horst, H A;
- Leithäuser, M;
- Dührsen, U;
- Reinke, P;
- Lebranchu, Y;
- Neuhaus, R;
- Lehmkuhl, H;
- Tarella, C;
- Schlattmann, P;
- Riess, H;
- Leblond, V;
- Trappe, R U
Publication type:
Article
Phase 1b study of lenalidomide in combination with rituximab-CHOP (R2-CHOP) in patients with B-cell lymphoma.
Published in:
Leukemia (08876924), 2013, v. 27, n. 1, p. 252, doi. 10.1038/leu.2012.172
By:
- Tilly, H;
- Morschhauser, F;
- Salles, G;
- Casasnovas, R-O;
- Feugier, P;
- Molina, T J;
- Jardin, F;
- Terriou, L;
- Haioun, C;
- Coiffier, B
Publication type:
Article
Prognostic value of real-time quantitative PCR (RQ-PCR) in AML with t(8;21).
Published in:
Leukemia (08876924), 2005, v. 19, n. 3, p. 367, doi. 10.1038/sj.leu.2403627
By:
- Leroy, H;
- de Botton, S;
- Grardel-Duflos, N;
- Darre, S;
- Leleu, X;
- Roumier, C;
- Morschhauser, F;
- Lai, J-L;
- Bauters, F;
- Fenaux, P;
- Preudhomme, C
Publication type:
Article
ZUMA‐22: A PHASE 3, RANDOMIZED CONTROLLED STUDY OF AXICABTAGENE CILOLEUCEL (AXI‐CEL) VS STANDARD‐OF‐CARE THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA.
Published in:
Hematological Oncology, 2023, v. 41, p. 853, doi. 10.1002/hon.3166_OT31
By:
- Flinn, I. W.;
- Jacobson, C. A.;
- Nastoupil, L. J.;
- Morschhauser, F.;
- Davies, A.;
- Buske, C.;
- Corradini, P.;
- Lopez‐Guillermo, A.;
- Reshef, R.;
- Parameswaran, V.;
- Sehgal, A.;
- Tees, M.;
- Lui, C.;
- Xue, W.;
- Beygi, S.;
- Grechko, N.;
- Bolsue, P.;
- Giovanetti, A.;
- To, C.;
- Nahas, M.
Publication type:
Article
KILT: A RANDOMIZED NON‐COMPARATIVE PHASE II LYSA STUDY OF LACUTAMAB WITH GEMOX VERSUS GEMOX IN RELAPSED/REFRACTORY PERIPHERAL T‐CELL LYMPHOMA.
Published in:
Hematological Oncology, 2023, v. 41, p. 838, doi. 10.1002/hon.3166_OT18
By:
- Cheminant, M.;
- Carras, S.;
- Bruneau, J.;
- Lemonnier, F.;
- Bachy, E.;
- Herbaux, C.;
- Feugier, P.;
- Daguindau, N.;
- Gastinne, T.;
- Guillermin, Y.;
- Lamarque, M.;
- Slama, B.;
- Wolfromm, A.;
- Morschhauser, F.;
- Tournilhac, O.;
- Gaulard, P.;
- Asnafi, V.;
- Ortonne, N.;
- Damaj, G.;
- Hermine, O.
Publication type:
Article
A PHASE 1 STUDY EVALUATING PRT2527, A POTENT AND HIGHLY SELECTIVE CDK9 INHIBITOR, IN PATIENTS WITH SELECT RELAPSED/REFRACTORY B‐CELL MALIGNANCIES.
Published in:
Hematological Oncology, 2023, v. 41, p. 829, doi. 10.1002/hon.3166_OT11
By:
- Cheson, B. D.;
- Morschhauser, F.;
- Assouline, S. E.;
- Michallet, A.;
- Tani, M.;
- Paris, G.;
- Sun, W.;
- Atwal, S. K.;
- Hong, W.;
- Sarkozy, C.
Publication type:
Article
TRANSCEND FL: PHASE 2 STUDY RESULTS OF LISOCABTAGENE MARALEUCEL (LISO‐CEL) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL).
Published in:
Hematological Oncology, 2023, v. 41, p. 877, doi. 10.1002/hon.3196_LBA4
By:
- Morschhauser, F.;
- Dahiya, S.;
- Palomba, M. L.;
- Garcia‐Sancho, A. M.;
- Ortega, J. L. Reguera;
- Kuruvilla, J.;
- Jager, U.;
- Cartron, G.;
- Izutsu, K.;
- Dreyling, M.;
- Kahl, B.;
- Ghesquieres, H.;
- Ardeshna, K.;
- Goto, H.;
- Barbui, A. M.;
- Abramson, J. S.;
- Borchmann, P.;
- Fleury, I.;
- Mielke, S.;
- Farazi, T.
Publication type:
Article
AXICABTAGENE CILOLEUCEL AS SECOND‐LINE THERAPY FOR LARGE B‐CELL LYMPHOMA IN TRANSPLANT‐INELIGIBLE PATIENTS: FINAL ANALYSIS OF ALYCANTE, A PHASE 2 LYSA STUDY.
Published in:
Hematological Oncology, 2023, v. 41, p. 147, doi. 10.1002/hon.3163_97
By:
- Houot, R.;
- Bachy, E.;
- Cartron, G.;
- Gros, F.;
- Morschhauser, F.;
- Oberic, L.;
- Gastinne, T.;
- Feugier, P.;
- Dulery, R.;
- Thieblemont, C.;
- Joris, M.;
- Jardin, F.;
- Choquet, S.;
- Casasnovas, O.;
- Brisou, G.;
- Cheminant, M.;
- Bay, J.;
- Gutierrez, F. Llamas;
- Menard, C.;
- Tarte, K.
Publication type:
Article
ZUMA‐23: A GLOBAL, PHASE 3, RANDOMIZED CONTROLLED STUDY OF AXICABTAGENE CILOLEUCEL VERSUS STANDARD OF CARE AS FIRST‐LINE THERAPY IN PATIENTS WITH HIGH‐RISK LARGE B‐CELL LYMPHOMA.
Published in:
Hematological Oncology, 2023, v. 41, p. 171, doi. 10.1002/hon.3163_T06
By:
- Westin, J.;
- Jacobson, C. A.;
- Chavez, J. C.;
- Sureda, A.;
- Morschhauser, F.;
- Glaß, B.;
- Dickinson, M.;
- Davies, A.;
- Flinn, I. W.;
- Maloney, D. G.;
- Chamuleau, M.;
- Tees, M.;
- Xue, A.;
- Shahani, S.;
- Nikolajeva, O.;
- Kang, J.;
- Kaplan, A.;
- Schupp, M.;
- Miao, H.;
- Rich, E. S.
Publication type:
Article
GLOFITAMAB MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) LARGE B‐CELL LYMPHOMA (LBCL): EXTENDED FOLLOW‐UP AND LANDMARK ANALYSES FROM A PIVOTAL PHASE II STUDY.
Published in:
Hematological Oncology, 2023, v. 41, p. 144, doi. 10.1002/hon.3163_95
By:
- Dickinson, M.;
- Carlo‐Stella, C.;
- Morschhauser, F.;
- Falchi, L.;
- Bachy, E.;
- Cartron, G.;
- Khan, C.;
- Tani, M.;
- Martinez‐Lopez, J.;
- Bartlett, N.;
- Salar, A.;
- Brody, J.;
- Leppä, S.;
- Mulvihill, E.;
- Lundberg, L.;
- Relf, J.;
- Xie, Y.;
- Bottos, A.;
- Humphrey, K.;
- Hutchings, M.
Publication type:
Article
COMBINING CD19‐4‐1BBL (RO7227166) WITH GLOFITAMAB IS SAFE AND SHOWS EARLY EFFICACY IN PATIENTS SUFFERING FROM RELAPSED OR REFRACTORY B‐CELL NON‐HODGKIN LYMPHOMA.
Published in:
Hematological Oncology, 2023, v. 41, p. 136, doi. 10.1002/hon.3163_91
By:
- Hutchings, M.;
- Dickinson, M.;
- Carlo‐Stella, C.;
- Morschhauser, F.;
- Bosch, F.;
- Gritti, G.;
- Townsend, W.;
- Bartlett, N. L.;
- Cartron, G.;
- Ghesquieres, H.;
- Houot, R.;
- Walter, H.;
- Offner, F.;
- Christiansen, A.;
- Dimier, N.;
- Jamois, C.;
- Harrop, E.;
- Herter, S.;
- Hölzlwimmer, G.;
- Keelara, A.
Publication type:
Article
OPEN‐LABEL PHASE 1/2 STUDY OF CC‐99282, A CEREBLON E3 LIGASE MODULATOR (CELMOD) AGENT ± RITUXIMAB, IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) NON‐HODGKIN LYMPHOMA (NHL).
Published in:
Hematological Oncology, 2023, v. 41, p. 134, doi. 10.1002/hon.3163_90
By:
- Michot, J. M.;
- Chavez, J.;
- Carpio, C.;
- Bachy, E.;
- Ferrari, S.;
- Morschhauser, F.;
- Jørgensen, J. M.;
- Cordoba, R.;
- Bories, P.;
- Patah, P.;
- de Moucheron, B.;
- Carrancio, S.;
- Guarinos, C.;
- Zheng, X.;
- Mei, C.;
- Pourdehnad, M.;
- Nastoupil, L.
Publication type:
Article
PHASE 1B/2A STUDY OF AZD4573 (CDK9I) AND ACALABRUTINIB IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA (R/R DLBCL).
Published in:
Hematological Oncology, 2023, v. 41, p. 129, doi. 10.1002/hon.3163_87
By:
- Danilov, A.;
- Gregory, G. P.;
- Morschhauser, F.;
- Cheah, C. Y.;
- Shah, H.;
- Jurczak, W.;
- Olabode, D.;
- Meyer, S.;
- Yoon, J. L.;
- Arduini, S.;
- Saeh, J.;
- Olsson, R. F.;
- Strati, P.
Publication type:
Article
CLONAL ARCHITECTURE OF RELAPSED OR REFRACTORY FOLLICULAR HELPER T‐CELL LYMPHOMA: AN ANCILLARY STUDY OF THE ORACLE TRIAL, A LYSA STUDY.
Published in:
Hematological Oncology, 2023, v. 41, p. 108, doi. 10.1002/hon.3163_69
By:
- Loyaux, R.;
- Sako, N.;
- Quang, V. Tran;
- Bachy, E.;
- Morschhauser, F.;
- Cartron, G.;
- Gressin, R.;
- Daguindau, N.;
- Le Gouill, S.;
- Wolfromm, A.;
- Bouabdallah, K.;
- Ysebaert, L.;
- Casasnovas, O.;
- Robe, C.;
- Delfau, M.;
- Dupuis, J.;
- De Leval, L.;
- Gaulard, P.;
- Sloma, I.;
- Lemonnier, F.
Publication type:
Article
RADIOMICS REFLECTING BOTH TUMOR AND HOST FEATURES IMPROVES OUTCOME PREDICTION IN FOLLICULAR LYMPHOMA.
Published in:
Hematological Oncology, 2023, v. 41, p. 94, doi. 10.1002/hon.3163_58
By:
- Rebaud, L.;
- Capobianco, N.;
- Spottiswoode, B.;
- Cottereau, A.;
- Trotman, J.;
- Feugier, P.;
- Nastoupil, L. J.;
- Bachy, E.;
- Flinn, I. W.;
- Haioun, C.;
- Ysebaert, L.;
- Bartlett, N. L.;
- Tilly, H.;
- Casasnovas, R.;
- Ricci, R.;
- Portugues, C.;
- Meignan, M.;
- Morschhauser, F.;
- Buvat, I.
Publication type:
Article
Encouraging complete responses (CRs) with CDK9 inhibitor AZD4573 in patients (pts) with relapsed/refractory (r/r) peripheral T‐cell Lymphoma (PTCL): Early trial analysis.
Published in:
Hematological Oncology, 2023, v. 41, p. 568, doi. 10.1002/hon.3164_425
By:
- Zinzani, P. L.;
- Feldman, T.;
- Collins, G.;
- Zain, J.;
- Khot, A.;
- Kim, J. S.;
- Morschhauser, F.;
- Kim, T. M.;
- Roderick, J.;
- Yoon, J. L.;
- Sharma, S.;
- Saeh, J.;
- Dai, J.;
- Reyes, R.;
- Olsson, R. F.;
- Shortt, J.
Publication type:
Article
Transfusion needs after CD19 CAR T‐cells for large B‐cell lymphoma: predictive factors and impact on outcome. A DESCAR‐T study.
Published in:
Hematological Oncology, 2023, v. 41, p. 534, doi. 10.1002/hon.3164_397
By:
- Vic, S.;
- Thibert, J.;
- Bachy, E.;
- Cartron, G.;
- Gastinne, T.;
- Morschhauser, F.;
- Le Bras, F.;
- Bouabdallah, K.;
- Despas, F.;
- Bay, J.;
- Rubio, M.;
- Mohty, M.;
- Casasnovas, O.;
- Choquet, S.;
- Castilla‐Llorente, C.;
- Guidez, S.;
- Loschi, M.;
- Guffroy, B.;
- Carras, S.;
- La Rochelle, L. Drieu
Publication type:
Article
Analysis of immune and high‐risk biomarkers in patients with relapsed or refractory mantle cell lymphoma treated with glofitamab monotherapy.
Published in:
Hematological Oncology, 2023, v. 41, p. 486, doi. 10.1002/hon.3164_357
By:
- Pham*, T. H.;
- Leung*, W.;
- Hamidi, H.;
- Dickinson, M.;
- Morschhauser, F.;
- Carlo‐Stella, C.;
- Humphrey, K.;
- Mulvihill, E.;
- Lundberg, L.;
- Filezac de L'Etang, A.;
- Qayum, N.;
- Bottos, A.;
- Phillips, T.
Publication type:
Article
Long term follow‐up of untreated/relapsing MCL patients with the Ibrutinib, obinutuzumab, and venetoclax combination.
Published in:
Hematological Oncology, 2023, v. 41, p. 478, doi. 10.1002/hon.3164_352
By:
- Le Gouill, S.;
- Morschhauser, F.;
- Chiron, D.;
- Bouabdallah, K.;
- Cartron, G.;
- Casasnovas, O.;
- Rule, S.;
- Bodet‐Milin, C.;
- Herbaux, C.;
- Gastinne, T.;
- Callanan, M.;
- Tessoulin, B.
Publication type:
Article
Comparison of overall survival of lisocabtagene maraleucel (liso‐cel) versus standard of care (SOC) adjusting for crossover in second‐line (2L) R/R large B‐cell lymphoma.
Published in:
Hematological Oncology, 2023, v. 41, p. 451, doi. 10.1002/hon.3164_332
By:
- Morschhauser, F.;
- Ghesquieres, H.;
- Kamdar, M.;
- Liu, F. F.;
- Chandler, C.;
- Crotta, A.;
- Klijn, S. L.;
- Elsada, A.;
- Previtali, A.;
- Chaillol, I.;
- Proskorovsky, I.;
- Schmitz, N.;
- Gisselbrecht, C.;
- Abramson, J. S.
Publication type:
Article
Combination of pixantrone with rituximab, ifosfamide and etoposide in relapsed/refractory aggressive non‐Hodgkin lymphoma. Results from a phase II LYSA study (PIVeR).
Published in:
Hematological Oncology, 2023, v. 41, p. 437, doi. 10.1002/hon.3164_322
By:
- Fornecker, L.;
- Delwail, V.;
- Thieblemont, C.;
- Ghesquieres, H.;
- Bouabdallah, K.;
- Tilly, H.;
- Le Calloch, R.;
- Morschhauser, F.;
- Costello, R.;
- Slama, B.;
- Gyan, E.;
- Chauchet, A.;
- Ngirabacu, M.;
- Durot, E.;
- Choquet, S.;
- Capdupuy, C.;
- Le Goff, M.;
- Voillat, L.;
- Snauwaert, S.;
- Amorim, S.
Publication type:
Article
Pola‐R‐CHP versus R‐CHOEP in young patients with high‐risk diffuse large B‐cell lymphoma.
Published in:
Hematological Oncology, 2023, v. 41, p. 420, doi. 10.1002/hon.3164_308
By:
- Lenz, G.;
- Tilly, H.;
- Ziepert, M.;
- Altmann, B.;
- Craine, V.;
- Yan, M.;
- Herbaux, C.;
- Frontzek, F.;
- Nickelsen, M.;
- Hirata, J.;
- Sahin, D.;
- Lee, C.;
- Morschhauser, F.;
- Schmitz, N.
Publication type:
Article
REALMA: Subset of patients with Marginal Zone Lymphomas from the French nationwide REALYSA real‐world prospective cohort.
Published in:
Hematological Oncology, 2023, v. 41, p. 387, doi. 10.1002/hon.3164_281
By:
- Bommier, C.;
- Donzel, M.;
- Rossi, C.;
- Fornecker, L.;
- Bijou, F.;
- Chauchet, A.;
- Lebras, L.;
- Ysebaert, L.;
- Haioun, C.;
- Bouabdallah, K.;
- Morineau, N.;
- Gastinne, T.;
- Amorim, S.;
- Jardin, F.;
- Abraham, J.;
- Lamy de la Chapelle, T.;
- Gressin, R.;
- Fouillet, L.;
- Fruchart, C.;
- Morschhauser, F.
Publication type:
Article
Prognostic Value of Lymphopenia and Total Metabolic Tumor Volume in Diffuse Large Cell Lymphoma of B Phenotype in the RT3 and REMARC trials—A LYSA retrospective analysis.
Published in:
Hematological Oncology, 2023, v. 41, p. 346, doi. 10.1002/hon.3164_248
By:
- Willaume, A.;
- Chartier, L.;
- Ricci, R.;
- Blanc‐Durand, P.;
- Amorim, S.;
- Haioun, C.;
- Thieblemont, C.;
- Legouill, S.;
- Casasnovas, O.;
- Morschhauser, F.;
- Jardin, F.;
- Pascal, L.
Publication type:
Article
Comparison of machine learning approaches for POD24 prediction based on pretreatment PET in follicular lymphoma patients (on behalf of CALYM/LYSA groups).
Published in:
Hematological Oncology, 2023, v. 41, p. 340, doi. 10.1002/hon.3164_243
By:
- Hoang, D. T.;
- Schalck, E.;
- Ricci, R.;
- Chartier, L.;
- Marlot, L.;
- Gomez, E.;
- Nadel, B.;
- Xerri, L.;
- Morschhauser, F.;
- Kanoun, S.;
- Rossi, C.
Publication type:
Article
Cell‐free DNA sequencing allows the identification of the mutational profile of TFH lymphomas and has a predictive value: a LYSA study.
Published in:
Hematological Oncology, 2023, v. 41, p. 338, doi. 10.1002/hon.3164_241
By:
- Sako, N.;
- Delfau, M.;
- Bachy, E.;
- Morschhauser, F.;
- Cartron, G.;
- Casasnovas, O.;
- Gressin, R.;
- Daguindau, N.;
- Tournilhac, O.;
- Bouabdallah, K.;
- Le Gouill, S.;
- Andre, M.;
- Robe, C.;
- Dupuis, J.;
- De Leval, L.;
- Gaulard, P.;
- Lemonnier, F.
Publication type:
Article
TAyloring LYmphoma therapy with Immune Escape Signatures from 3D avatars of B‐cell NHL.
Published in:
Hematological Oncology, 2023, v. 41, p. 286, doi. 10.1002/hon.3164_197
By:
- Gava, F.;
- Faria, C.;
- Gravelle, P.;
- Garcia‐Valero, J.;
- Quelen, C.;
- Serrat, N.;
- Gower, N.;
- Morschhauser, F.;
- Fournié, J.;
- Bouquet, F.;
- Fonseca, C.;
- Herter, S.;
- Codarri, L.;
- McCord, R.;
- Chiang, E.;
- Laurent, C.;
- Perez‐Galan, P.;
- Ysebaert, L.;
- Bezombes, C.
Publication type:
Article
Identification of an activated/memory B‐cell signature of poor outcome and sensitivity to lenalidomide in follicular lymphoma patients.
Published in:
Hematological Oncology, 2023, v. 41, p. 288, doi. 10.1002/hon.3164_199
By:
- Laurent, C.;
- Trisal, P.;
- Tesson, B.;
- Lesne, B.;
- Van‐Acker, N.;
- Chartier, L.;
- Stokes, M.;
- Huang, C.;
- Huet, S.;
- Morschhauser, F.;
- Gandhi, A. K;
- Xerri, L.
Publication type:
Article
Study of the efficacy of novel bispecific antibodies targeting immune checkpoints in a 3D model of B non‐Hodgkin lymphoma.
Published in:
Hematological Oncology, 2023, v. 41, p. 287, doi. 10.1002/hon.3164_198
By:
- Gower, N.;
- Gava, F.;
- Rimailho, L.;
- Faria, C.;
- Gravelle, P.;
- Perez‐Galan, P.;
- Serrat, N.;
- Bouquet, F.;
- Fonseca, C.;
- Herter, S.;
- Codarri, L.;
- McCord, R.;
- Chiang, E.;
- Morschhauser, F.;
- Ysebaert, L.;
- Laurent, C.;
- Bezombes, C.
Publication type:
Article
IMMUNE CONTEXTURE ANALYSIS IN POLARIX SUGGESTS RESPONSE TO POLA‐R‐CHP TREATMENT REDUCES TUMOR MICROENVIRONMENT DEPENDENCY.
Published in:
Hematological Oncology, 2023, v. 41, p. 223, doi. 10.1002/hon.3163_146
By:
- Morschhauser, F.;
- Hatzi, K.;
- Lenz, G.;
- Herrera, A. F.;
- Flowers, C. R.;
- Trněný, M.;
- Burke, J. M.;
- Hou, J.;
- Staber, P. B.;
- Hawkes, E. A.;
- Izutsu, K.;
- Le Gouill, S.;
- Belada, D.;
- Tucci, A.;
- Yan, M.;
- Harris, W.;
- Hirata, J.;
- Lee, C.;
- Jiang, Y.;
- Jardin, F.
Publication type:
Article
EARLY CTDNA CLEARANCE AFTER CAR T‐CELL INFUSION PREDICTS OUTCOME IN PATIENTS WITH LARGE B‐CELL LYMPHOMA : RESULTS FROM ALYCANTE, A PHASE 2 LYSA STUDY.
Published in:
Hematological Oncology, 2023, v. 41, p. 179, doi. 10.1002/hon.3163_113
By:
- Delfau‐Larue, M.;
- Viailly, P.;
- Cartron, G.;
- Morschhauser, F.;
- Gros, F.;
- Gastinne, T.;
- Oberic, L.;
- Bachy, E.;
- Dulery, R.;
- Feugier, P.;
- Menard, C.;
- Quelen, C.;
- Pangault, C.;
- Portugues, C.;
- Gomes, L.;
- Itti, E.;
- Bailly, C.;
- Lemonnier, F.;
- Laurent, C.;
- Houot, R.
Publication type:
Article
CIRCULATING TUMOR DNA (CTDNA) STATUS AND CLINICAL OUTCOMES IN PATIENTS (PTS) WITH PREVIOUSLY UNTREATED DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL) IN THE POLARIX STUDY.
Published in:
Hematological Oncology, 2023, v. 41, p. 175, doi. 10.1002/hon.3163_111
By:
- Herrera, A. F.;
- Tracy, S.;
- Sehn, L. H.;
- Jardin, F.;
- Lenz, G.;
- Trněný, M.;
- Salles, G.;
- Flowers, C. R.;
- Tilly, H.;
- Sharman, J. P.;
- Friedberg, J. W.;
- Balasubramanian, S.;
- Raghavan, V.;
- Hirata, J.;
- Lee, C.;
- Jiang, Y.;
- Morschhauser, F.
Publication type:
Article
VERY LONG‐TERM FOLLOW‐UP OF RITUXIMAB MAINTENANCE IN YOUNG PATIENTS WITH MANTLE CELL LYMPHOMA INCLUDED IN THE LYMA TRIAL, A LYSA STUDY.
Published in:
Hematological Oncology, 2023, v. 41, p. 151, doi. 10.1002/hon.3163_100
By:
- Sarkozy, C.;
- Thieblemont, C.;
- Oberic, L.;
- Moreau, A.;
- Bouabdallah, K.;
- Damaj, G.;
- Gastine, T.;
- Ribrag, V.;
- Casasnovas, O.;
- Haioun, C.;
- Houot, R.;
- Jardin, F.;
- Van Den Neste, E.;
- Cheminant, M.;
- Morschhauser, F.;
- Callana, M.;
- Ghesquieres, H.;
- Gressin, R.;
- Hermine, O.;
- Le Gouill, S.
Publication type:
Article
SELINEXOR IN COMBINATION WITH R‐GDP FOR PATIENTS WITH RELAPSED/REFRACTORY B‐CELL LYMPHOMA: PRELIMINARY RESULTS OF THE SELINDA PHASE IB LYSA STUDY (EUDRACT NUMBER: 2015‐005612‐15)
Published in:
Hematological Oncology, 2021, v. 39, p. 1, doi. 10.1002/hon.88_2880
By:
- Maerevoet, M.;
- Casasnovas, O.;
- Cartron, G.;
- Morschhauser, F.;
- Thieblemont, C.;
- Bouabdallah, K.;
- Feugier, P.;
- Szablewski, V.;
- Becker, S.;
- Tilly, H.
Publication type:
Article
SELINEXOR IN COMBINATION WITH R‐GDP FOR PATIENTS WITH RELAPSED/REFRACTORY B‐CELL LYMPHOMA: PRELIMINARY RESULTS OF THE SELINDA PHASE IB LYSA STUDY (EUDRACT NUMBER: 2015‐005612‐15)
Published in:
Hematological Oncology, 2021, v. 39, p. 1, doi. 10.1002/hon.87_2880
By:
- Maerevoet, M.;
- Casasnovas, O.;
- Cartron, G.;
- Morschhauser, F.;
- Thieblemont, C.;
- Bouabdallah, K.;
- Feugier, P.;
- Szablewski, V.;
- Becker, S.;
- Tilly, H.
Publication type:
Article
FIRST RESULTS OF DLBCL PATIENTS TREATED WITH CAR‐T CELLS AND ENROLLED IN DESCAR‐T REGISTRY, A FRENCH REAL‐LIFE DATABASE FOR CAR‐T CELLS IN HEMATOLOGIC MALIGNANCIES.
Published in:
Hematological Oncology, 2021, v. 39, p. 1, doi. 10.1002/hon.84_2879
By:
- Le Gouill, S.;
- Bachy, E.;
- Di Blasi, R.;
- Cartron, G.;
- Beauvais, D.;
- Le Bras, F.;
- Gros, François‐X.;
- Choquet, S.;
- Bories, P.;
- Rubio, Marie‐Thérès.;
- Casasnovas, René‐O.;
- Bounaix, L.;
- Mohty, M.;
- Joris, M.;
- Gastinne, T.;
- Sesques, P.;
- Tudesq, J. J.;
- Morschhauser, F.;
- Gat, E.;
- Broussais, F.
Publication type:
Article
PHASE II TRIAL OF RITUXIMAB PLUS CHLORAMBUCIL FOLLOWED BY A 2‐YEAR SUBCUTANEOUS RITUXIMAB MAINTENANCE IN MALT LYMPHOMA PATIENTS (IELSG38)
Published in:
Hematological Oncology, 2021, v. 39, p. 1, doi. 10.1002/hon.79_2879
By:
- Pirosa, M. C.;
- Orsucci, L.;
- Feugier, P.;
- Tani, M.;
- Ghesquieres, Hervé;
- Musuraca, G.;
- Baldini, L.;
- Merli, F.;
- De Renzis, B.;
- Gyan, E.;
- Gini, G.;
- Marino, D.;
- Gressin, R.;
- Morschhauser, F.;
- Palombi, F.;
- Cavallo, F.;
- Conconi, A.;
- Le Gouill, S.;
- Tilly, Hervé;
- Zanni, M.
Publication type:
Article
ATEZOLIZUMAB + OBINUTUZUMAB + VENETOCLAX IN PATIENTS WITH RELAPSED OR REFRACTORY MARGINAL ZONE LYMPHOMA: PRIMARY ANALYSIS OF A PHASE 2 TRIAL FROM LYSA.
Published in:
Hematological Oncology, 2021, v. 39, p. 1, doi. 10.1002/hon.57_2880
By:
- Herbaux, C.;
- Schiano de Colella, J. M.;
- Thieblemont, C.;
- Guidez, S.;
- Ysebaert, L.;
- Tilly, H.;
- Le Gouill, S.;
- Houot, R.;
- Bachy, E.;
- Laurent, C.;
- Damaj, G.;
- Feugier, P.;
- Morineau, N.;
- Tarte, K.;
- Morschhauser, F.;
- Cartron, G.
Publication type:
Article
ACALABRUTINIB MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA: FINAL RESULTS FROM A PHASE 2 STUDY.
Published in:
Hematological Oncology, 2021, v. 39, p. 1, doi. 10.1002/hon.58_2880
By:
- Wang, M.;
- Rule, S.;
- Zinzani, P. L.;
- Goy, A.;
- Casasnovas, O.;
- Smith, S. D.;
- Damaj, G.;
- Doorduijn, J. K.;
- Lamy, T.;
- Morschhauser, F.;
- Panizo, C.;
- Shah, B.;
- Davies, A.;
- Eek, R.;
- Dupuis, J.;
- Jacobsen, E.;
- Kater, A. P.;
- Le Gouill, S.;
- Oberic, L.;
- Robak, T.
Publication type:
Article
EARLY POSITRON EMISSION TOMOGRAPHY RESPONSE‐ADAPTED TREATMENT IN LOCALIZED DIFFUSE LARGE B‐CELL LYMPHOMA (AAIPI=0) : RESULTS OF THE PHASE 3 LYSA LNH 09‐1B TRIAL.
Published in:
Hematological Oncology, 2021, v. 39, p. 1, doi. 10.1002/hon.5_2879
By:
- Bologna, S;
- Vander Borght, T;
- Briere, J;
- Ribrag, V;
- Damaj, G. L;
- Thieblemont, C;
- Feugier, P;
- Peyrade, F;
- Lebras, L;
- Coso, D;
- Sibon, D;
- Bonnet, C;
- Morschhauser, F;
- Ghesquieres, H;
- Becker, S;
- Olivier, P;
- Fabiani, B;
- Tilly, H;
- Haioun, C;
- Bastie, J. N
Publication type:
Article
CIRCULATING TUMOR DNA LOAD AND TOTAL METABOLIC TUMOR VOLUME IN DIFFUSE LARGE B CELL LYMPHOMA (DLBCL) PATIENTS TREATED BY R‐CHOP – FROM REMARC, A LYSA STUDY.
Published in:
Hematological Oncology, 2021, v. 39, p. 1, doi. 10.1002/hon.3_2880
By:
- Bohers, E;
- Delfau‐Larue, M;
- Vercellino, L;
- Cottereau, A;
- Viennot, M;
- Viailly, P;
- Salles, G;
- Tilly, H;
- Damaj, G;
- Haioun, C;
- Ribrag, V;
- Morschhauser, F;
- Casasnovas, R;
- Nicolas‐Virelizier, E;
- Feugier, P;
- Bouabdallah, R;
- Cartron, G;
- Renaud, L;
- Chartier, L;
- Portugues, C
Publication type:
Article
CHARACTERISTICS OF PATIENTS ACHIEVING COMPLETE OR PARTIAL RESPONSE (CR/PR) WITH TAZEMETOSTAT (TAZ) IN WILD‐TYPE RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL)
Published in:
Hematological Oncology, 2021, v. 39, p. 1, doi. 10.1002/hon.21_2880
By:
- Batlevi, C. L.;
- Salles, G.;
- Tilly, H.;
- Chaidos, A.;
- McKay, P.;
- Phillips, T.;
- Assouline, S.;
- Campbell, P.;
- Ribrag, V.;
- Damaj, G. Laurent;
- Dickinson, M.;
- Jurczak, W.;
- Kaźmierczak, M.;
- Opat, S.;
- Radford, J. R.;
- Schmitt, A.;
- Rajarethinam, A.;
- Shang, G.;
- Morschhauser, F.
Publication type:
Article
THREE PHASE 1/2, OPEN‐LABEL STUDIES OF CEREBLON E3 LIGASE MODULATOR (CELMOD)‐BASED REGIMENS IN NEWLY DIAGNOSED (ND) OR RELAPSED/REFRACTORY (R/R) NON‐HODGKIN LYMPHOMA (NHL)
Published in:
Hematological Oncology, 2021, v. 39, p. 1, doi. 10.1002/hon.173_2880
By:
- Morschhauser, F.;
- Nowakowski, G. S.;
- Cartron, G.;
- Kesanakurthy, V.;
- Gkasiamis, A.;
- Patah, P.;
- Delarue, R.;
- Wang, T.;
- Li, J.;
- Xian, D.;
- Fox, C. P.;
- Martin, P.
Publication type:
Article
GLOFITAMAB STEP‐UP DOSING: UPDATED EFFICACY DATA SHOW HIGH COMPLETE RESPONSE RATES IN HEAVILY PRETREATED RELAPSED/REFRACTORY (R/R) NON‐HODGKIN LYMPHOMA (NHL) PATIENTS.
Published in:
Hematological Oncology, 2021, v. 39, p. 1, doi. 10.1002/hon.15_2879
By:
- Carlo‐Stella, C;
- Hutchings, M;
- Offner, F. C;
- Morschhauser, F;
- Bachy, E;
- Crump, M;
- Sureda, A;
- Iacoboni, G;
- Haioun, C;
- Perez‐Callejo, D;
- Lundberg, L;
- Relf, J;
- Clark, E;
- Carlile, D;
- Piccione, E;
- Belousov, A;
- Humphrey, K;
- Dickinson, M. J
Publication type:
Article

Found: 97